C-Met and TRK are well studied kinases in different cancers, and blocking these kinases has been demonstrated to be an effective strategy for the treatment of hepatocellular carcinoma and sarcomas with NTRK fusion. The gene discussed is MET; the disease is hepatocellular carcinoma.